Biomerica Plans Launch of InFoods® IBS Test; Names Robert Carlson as Chief Commercial Officer
August 30, 2022 08:19 ET
|
Biomerica, Inc.
InFoods® IBS commercial launch and revenues expected before the close of calendar year 2022Mr. Carlson is an accomplished and performance-driven Commercial and Corporate Strategy and Development...
Biomerica Reports 111% Increase in Q3 Fiscal 2022 Revenues to $7.6 million vs. Q3 Fiscal 2021
April 14, 2022 08:37 ET
|
Biomerica, Inc.
Q3 Net loss per share of $0.01 vs. a net loss of $0.18 per share from same period last year InFoods® IBS diagnostic-guided therapy clinical trial results demonstrated statistically significant...
Biomerica Announces Positive Topline Results from the Endpoint Clinical Trial of its InFoods® IBS Treatment for Patients with Irritable Bowel Syndrome
February 08, 2022 06:39 ET
|
Biomerica, Inc.
InFoods® IBS Diagnostic-Guided Therapy is the first therapy of its kind using science, diet and technology to identify patient specific foods, which when eliminated, help reduce the symptoms of IBS...
Jasco Introduces New JascoPro Brand at International Builder Show
February 07, 2022 08:00 ET
|
Jasco
OKLAHOMA CITY, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Connected home leader, Jasco, today unveils the new JascoPro Series brand at the International Builder Show in Orlando. Exclusive to the professional...
Scientists and Nutritionists Collaborate on a New, Powerful Gut Health Dietary Supplement
February 04, 2022 09:00 ET
|
Synesis Nutrition, Inc.
CAMBRIDGE, Wis., Feb. 04, 2022 (GLOBE NEWSWIRE) -- Wisconsin-based nutrition and food chemistry experts at Synesis Nutrition, Inc. have collaborated on the development of a unique new product that...
Biomerica Announces Preliminary Second Quarter Revenue Increase of Approximately 238%, to Approximately $4.6 Million
December 16, 2021 08:19 ET
|
Biomerica, Inc.
InFoods® IBS Clinical Trial on Track for Completion in December with Topline Results Expected to be Announced in January, 2022. IRVINE, Calif., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Biomerica, Inc....
New Study Shows Patients With Irritable Bowel Syndrome and Functional Dyspepsia Experience High Levels of Bloating and Distension
December 09, 2021 09:00 ET
|
Rome Foundation
RALEIGH, N.C., Dec. 09, 2021 (GLOBE NEWSWIRE) -- The Rome Foundation Research Institute and Danone Nutricia Research have partnered on a study to look at the prevalence of bloating and distension in...
Rome Foundation Releases Clinical Criteria to Better Meet Needs of Patients
November 29, 2021 09:00 ET
|
Rome Foundation
RALEIGH, N.C., Nov. 29, 2021 (GLOBE NEWSWIRE) -- The Rome Foundation has published a groundbreaking modification of the Rome IV diagnostic criteria of the Disorders of Gut Brain Interaction (DGBI -...
Biomerica expects Completion of Patient Enrollment for its InFoods® Diagnostic-Guided Therapy Irritable Bowel Syndrome Clinical Trial this week
August 30, 2021 08:19 ET
|
Biomerica, Inc.
Final patients to compete this double blinded trial by end of October. Top-Line trial results expected by year end.The InFoods® IBS Diagnostic-Guided Therapy is the first therapy of its kind for...
Biomerica Announces Notice of Allowance for Patent on Product used to Diagnose and Treat Depression
August 11, 2021 08:19 ET
|
Biomerica, Inc.
Hundreds of millions of people worldwide suffer from depression IRVINE, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA) announced today that the Japanese Patent Office has...